AI assistant
Sending…
EyePoint Pharmaceuticals, Inc. — Director's Dealing 2026
Feb 18, 2026
32254_dirs_2026-02-18_661c6667-3396-4bab-b374-b77d1bb47410.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: EyePoint, Inc. (EYPT)
CIK: 0001314102
Period of Report: 2026-02-17
Reporting Person: Ribeiro Ramiro (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2026-02-17 | Common Stock | M | 2437.00 | $8.26 | Acquired | 2437.00 | Direct |
| 2026-02-17 | Common Stock | S | 2437.00 | $15.00 | Disposed | 0.00 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2026-02-17 | Stock Option (Right to Buy) | $8.26 | M | 2437.00 | Disposed | 2035-01-03 | Common Stock (2437.00) | Direct |
Footnotes
F1: The option to purchase will vest and become exercisable as follows: 25% at January 3, 2026 and the remainder ratably, on a monthly basis, over the remaining three years.
More from EyePoint Pharmaceuticals, Inc.
Regulatory Filings
2026
May 14
Regulatory Filings
2026
May 6
Investor Presentation
2026
Apr 13
Director's Dealing
2026
Mar 24
Legal Proceedings Report
2026
Mar 20
Regulatory Filings
2026
Mar 4
Regulatory Filings
2026
Mar 2
Major Shareholding Notification
2026
Feb 12
Director's Dealing
2026
Jan 7
Regulatory Filings
2026
Jan 7